Sugi Predict

Sugi Predict / Compounds / SCHEMBL383392

SCHEMBL383392

SCHEMBL383392

CCOC(=O)C(CO)(COC(=O)C(C)(C)C)C(=O)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 4/20 0.44
▸ CYP4A11 Q02928 4/20 0.44
▸ PKM P14618 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ PRKCA P17252 1/20 0.38
▸ MMP8 P22894 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ TSHR P16473 2/20 0.33
▸ THRB P10828 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ PMP22 Q01453 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ BTN3A1 O00481 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13130098 0.91 PKM (0.42) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL13190756 0.88 CYP4F2 (0.39) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL12963339 0.86 MEN1 (0.43) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL13173223 0.83 MEN1 (0.41) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL383194 0.82 ALDH1A1 (0.50) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL13765489 0.81 MEN1 (0.40) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL371475 0.81 PKM (0.52) CYP4F2CYP4A11PKMMEN1KMT2A
Alcohol SCHEMBL12506185 0.81 CYP4F2 (0.55) CYP4F2CYP4A11PKMMEN1KMT2A
SCHEMBL126096 0.81 — —
SCHEMBL13020677 0.80 MMP8 (0.50) CYP4F2CYP4A11PKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2623104-A1 Substituted nucleoside and nucleotide analogs Alios Biopharma, Inc. (US) 2013-08-07 — — EP disclosed
EP-2623104-A1 Substituted nucleoside and nucleotide analogs Alios Biopharma, Inc. (US) 2013-08-07 — — EP disclosed
EP-2408306-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS Alios Biopharma, Inc. (US) 2012-01-25 — — EP disclosed
WO-2011005595-A2 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2011-01-13 — — WO disclosed
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 — — US disclosed
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 — — US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 — — US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 — — US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 — — US disclosed
US-20100240604-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-23 — — US disclosed
US-20100240604-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-23 — — US disclosed
WO-2010108140-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-23 — — WO disclosed
US-20090181921-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA INC. (US) 2009-07-16 — — US disclosed
US-20090181921-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA INC. (US) 2009-07-16 — — US disclosed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO disclosed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO disclosed
WO-2009086201-A1 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO disclosed
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC. (US) 2009-07-09 — — US disclosed
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC. (US) 2009-07-09 — — US disclosed
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC. (US) 2009-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS NTPCR, NT5C2, PNP CYP4F2 2905/4885CYP4A11 2141/4885PKM 3252/4885
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE RNASEL, RNASE1, RNASEH1 CYP4F2 3238/4885CYP4A11 3627/4885PKM 2688/4885
US-20090181921-A1 2-5A ANALOGS AND THEIR METHODS OF USE RNASEL, RNASE1, RNASEH1 CYP4F2 2863/4885CYP4A11 3237/4885PKM 2491/4885
US-20100240604-A1 PROTECTED NUCLEOTIDE ANALOGS PNP, NTPCR, TYMP CYP4F2 3261/4885CYP4A11 2691/4885PKM 1544/4885
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS PNP, TYMP, NTPCR CYP4F2 3498/4885CYP4A11 2729/4885PKM 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.